Drugs / LY3056480
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05061758 | Sep 2022 → Sep 2024 | sensorineural hearing loss disorder | Audion Therapeutics BV | Withdrawn | Missed primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-03-04 | Audion Therapeutics BV | Results Audion Therapeutics and the REGAIN Consortium Announce Publication in Nature Communications audiontherapeutics.com ↗
The Phase I part of the study (Multiple Ascending Dose of 3 administrations) confirms safety and tolerability of a dose of 250 microgram of Gamma Secretase Inhibitor LY3056480. |
| 2019-02-05 | Audion Therapeutics BV | Results Audion Therapeutics and REGAIN Consortium Announce Positive Phase I Results in Patients with Sensorineural Hearing Loss audiontherapeutics.com ↗
Repeated intratympanic administration of LY3056480 is well tolerated and safe and in subgroups of patients a long term positive effect on multiple hearing tests is seen. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-03-04 | Audion Therapeutics BV | Audion Therapeutics and the REGAIN Consortium Announce Publication in Nature Communications audiontherapeutics.com ↗ |
| 2019-02-05 | Audion Therapeutics BV | Audion Therapeutics and REGAIN Consortium Announce Positive Phase I Results in Patients with Sensorineural Hearing Loss audiontherapeutics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3056480 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05061758 ↗ |
| Action | Inhibit | “LY3056480 is an inhibitor of gamma-secretase” NCT05061758 ↗ |
| Route | Other | “administered trans-tympanically into one ear” NCT05061758 ↗ |